Facilitating Medication Reconciliation with Animation and Spatial layout Leo Claudino¹, Sameh Khamis¹, Ran Liu¹, Ben London¹, Jay Pujara¹ Catherine Plaisant², Ben Shneiderman^{1, 2} ¹Department of Computer Science, ²HCIL, University of Maryland, College Park, MD

Abstract

Our project looks at novel user interfaces to facilitate medication reconciliation. We are focusing on the user interface that physicians might use to compare and merge two separate lists of medications. Similarities and differences between the lists need to be identified; decisions need to be made as to which medications should be continued and which ones should be stopped. We describe a novel prototype called TwinList that uses animation and spatial layout to reveal similarities, and color to highlight differences in similar medications. Simple interactive controls facilitate the selection of sets of medications to be continued or stopped. We are in the early stages of user evaluation.

Introduction

Within the medical community, there has been much research highlighting the need for improved medication reconciliation [1-6]. Preventable Adverse Drug Events (PADEs) are involved in 19% of post-treatment complications. Trial implementations of medication reconciliation policies show significant improvements. In one study, 94% of patients had some medication errors, of which a medication reconciliation process eliminated nearly all [6].

The entire process of medication reconciliation is a complex collaborative process in which many things can go wrong: the patients may not recall what medications they are taking (or may even be unconscious); the information may not be recorded properly and include a lot of unreported uncertainty (e.g. about dosage); the record of past medication orders may not be complete or not even be accessible at all; not all sources of medication orders for the patient may be known (e.g. they may have consulted a specialist on their own), etc. Eventually the physician is presented with multiple lists of medications from different sources (see Figure 1) which need to be reconciled into a single list that will be signed and saved in the medical record of the patient. Our focus has been on this last step of the process: facilitating the task of reviewing and sorting the medications that need to be continued from those that need to be stopped, following a careful and often iterative decision making process. Our interviews of physicians suggest that they do not have adequate tools or a well-described workflow to perform the medication reconciliation.




Figure 1: Example situations of medication reconciliation

Early prototypes

A first paper prototype was developed in collaboration with colleagues from the University of Texas at Houston and the University of Kentucky, and has been described in a separate paper [7]. It identified four levels of drug equivalence (Figure 1) and presents the matches between the two lists with a classic table view, using color highlighting to indicate matches (Figure 2).

Equivalence	Criteria
Form Equivalence	Identical except for brand vs. generic
Functional Equivalence	Same therapeutic intent
Partial Equivalence	Form or functional equivalence, but differ in dosage, frequency, or route
No equivalence	Unique in form and function

Figure 2. Four levels of drug equivalence – From [7].

	0	riginal Lists		Reconci	le Lists		A	pprove	
	_		Co	nsolidated	Record				
Entry	Origin	Medication	Dosage	Frequency	Start Date	End Date	Form	Relation	
1	Dr. P	Zoloft Sertraline HCI	50 MG	q.d.	05/22/2006 03/22/2007	Continuous	Oral	Brand Generic	
2	Dr. P	Vicodin ► Acetaminophen	5/500 MG 325 MG	q.d.	05/22/2006 03/22/2007	Continuous	Oral	Brand Generic	
3	Dr.	Levaquin	10 MG	q.d.	02/25/2009	03/10/2009	Oral	Unique	
			R	econciled	Record				
Entry	Origin	Medication	Dosage	Frequency	Start Date	End Date	Form	Alerts	
1	Both	Quinapril	40 MG	b.i.d.	12/15/2000	Continuous	Oral	6	
2	Both	Warfarin	5 MG	q.d.	09/07/2008	03/06/2009	Oral	DI, E	=
3	Both	Lipitor	10 MG	q.d.	12/15/2000	Continuous	Oral	DI, F	\equiv
4	Both	Sotalol	80 MG	q.d.	12/15/2000	Continuous	Oral	6	

Figure 3: Example of a tabular interface used for presenting two medication lists combined in one table, from an earlier prototype [7]. After the two lists have been processed the drugs that are exactly the same in both lists (color coded in green) are automatically moved to the reconciled list (at the bottom). The remaining drugs are color coded. The drugs that appear only in one list are highlighted in red. The drugs that are similar but not an exact match between the two lists are grouped together in one large row and highlighted in yellow.

TwinList: a new prototype using animation and layout to show similarity

Here our goal was to investigate alternative ways of presenting the similarity information data. We developed TwinList, a prototype that uses spatial layout, color coding and animation to convey the similarity and differences between the lists (Figure 4 and 5). This prototype was developed by a team of students of the University of Maryland Computer Science department as a project for the Information Visualization class [8].

Using a spatial organization of data, we provide an intuitive way for users to quickly differentiate items that are the same from those that differ between the two lists. We used 3 categories: drugs are "identical" when they appear in both lists, "unique" when they appear in one list only, and others are "similar" when the drug has some level of equivalence with another drug in the other list (either form equivalence, functional equivalence or partial equivalence). We use animation to help users understand each step of the list comparison process; see Figure 4 (and video http://www.cs.umd.edu/hcil/sharp/slides/twinlist-v2-symposium-1024by768.mp4 . In addition, Twinlist provides grouping of the drugs by therapeutic use, which may be useful when the lists are very long.


After the medications have been reorganized to show similarities and differences users need to decide which medications will remain in the final reconciled list by accepting or rejecting drugs individually or as a group. Clicking on a drug brings a popup menu with the option to "Accept" or "Reject" it. Once the user has selected "Accept" or "Reject", the item is added to the top of either the Accepted or Rejected lists (Figure 5); the corresponding List Viewer item is either removed or grayed-out, according to the user-configurable option (which can be set in the Options Panel). Actions can be reversed if needed. More importantly physicians can accept or reject an entire column of drugs for example all the identical drugs, or all unique drugs from one list or the other.

winList Mate	h Lists Separate Patient	Find Identical Find Unique	E.R.	
	Patient (Accept All)		E.R. (Accept All)	
	Acetaminophen P0 35 mg steh Aspirin P0 81 mg steh Atorvistatin P0 45 mg steh Calcitrol P0 45 mg steh Calcitrol C		Acetaminophen P0 32smg ath Alarvistatin P0 60mg athy Calcitrol P0 62mg athy Calcitrol P0 62mg athy P0 72mg at	
intint (Separate	Find Identical Find Unique	Find Similar	
vinList Res	Patient	Identical	E.R.	_
	(Accept All)	(Accept All)	(Accept All)	
	Aspirin PO 81 mg daily Atorvistatin PO 40 mg daily	Acetaminophen P0 325 mg q4h Calcitrol	Atorvistatin PO 60 mg daily Calcium Carbonate	
	Calcium Carbonate PO 500 mg TID CC	PO 0.25 mg daily	PO 1000 mg TID CC Ciproflaxocin PO 500 mg daily	
	Meloxicam PO 7.5 mg daily Metoprolol PO 50 mg daily	Darbepoetin SC 60 mg qFriday Docusate Sodium PO 100 mg BID	Ferrous Gloconate PO 300 mg TID Metoprofol PO 100 mg BID Orneprazole PO 40 mg daily	
		Ramipril P0 5 mg daily		
winList Res	set View Separate	Find Identical Find Unique	Find Similar	
Patient	Patient	Identical	E.R.	E.R. Unique
Patient Unique (Accept All)		Identical (Accent All) Acetaminophen PO 325 mg q4h	E.R. (Accept All) Atorvistatin PO 60 mg daily	E.R. Unique (Accest All)
Patient Unique (Accept AII)	Patient (Accept All)	Identical (AccestAll) Acetamicophen PO 325 mg eth Calcitrol PO 625 mg daily Darbepoetin SC 60 mg eFriday	E.R. (Accept All)	E.R. Unique Leased.ntll
Patient Unique (docated) Aspirin PO 61 mg daily Meloxicam	Patient Accept All Adorwistatin Po 40 mg daty Calcium Carbonate	Identical (Accest All) Accetaminophen PO 325 mg eth Calcitrol PO 0.25 mg daily	E.R. (Accert All) Atorvistatin PO 60 mg daity Calcium Carbonate	Unique (Accest AII)
Patient Unique (docated) Aspirin Po 61 mg daily Meloxicam	Patient (Accest A) Atorvistalin Po 40 mg daty Calcium Carbonate Po 500 mg TD CC	Identical Lacatal Acetaminophen P0 325 mg e8 Calcitrol P0 625 mg daily Darbepoetin Sc 60 mg driday Docusate Sodium	E.R. LossetAD Alorvistatin P0 60 mg daily Calcium Carbonate P0 1000 mg TD CC	Unique Lecast.till Ciproflaxocin Po 500 mg daily Ferrous Gloconate
Patient Unique Coordidu Asprim 00 81 mg daily Weboxicam No 75 mg daily	Patient (Accest A) Atorvistalin Po 40 mg daty Calcium Carbonate Po 500 mg TD CC	Identical (docat/d) Acdaminophen P0 328 mg en Calcitrol P0 828 mg daily Darbepoetin Sc 80 mg driday Docusate Sodium P0 100 mg ab	E.R. Licosat Al) Alcovistatin po 60 mg daly Calcium Carbonate po 1000 mg TD CC	Unique Locast.att
Patient Unique Coordidu Asprim Meloxicam Meloxicam No 7.5 mg daiy winList Patient	Patient (Accest(A)) Atorvisiatin Po 40 ng caty Calcium Carbonate Po 500 ng tro co Metoproiol Po 50 ng caty Metoproiol	Identical (Accelarinicophen Po 325 mg effe Calcitrol Pro 8 25 mg daily Darbepoetin so 6 mg daily Po dagened Ramippil Po 5 mg daily Po for ga daily Po for ga daily Po for ga daily	E.R. (scat.40) Alovestatin Po 60 mg day Calcium Carbonate po 1000 mg TID CC Metoproiol po 100 mg BD	Ciproflaxocin Po 560 mg dairy Ferrous Gloconate Po 200 mg 10 Omeprazole Po 40 mg dairy
Petert Unique discatidui spirin ot mg daly feloxicam 0 75 mg daly	Patient /Atorvisialin Po 40 mg daty Calcium Carbonate Po 500 mg Tio CC Metoproiol Po 50 mg daty Metoproiol Po 50 mg daty Metoproiol Po 50 mg daty Patient	Identical (Acceld All) Accelaminophen po 326 mg eth Calcitrol po 6 25 mg daily Darbepoetin Sc 80 mg daily Darbepoetin Sc 80 mg daily Docusate Sodium Po 100 mg BD Ramppil Po 5 mg daily Ramppil Po 5 mg daily	E.R. Licost (AB) Alorvistatin Po 60 mg day Calcium Carbonate Po 1000 mg TD CC Metoprotol Po 100 mg BID	Ciproflaxocin Po 500 mg daiy Ferrous Gloconate Po 300 mg to Omeprazole Po 40 mg daiy
Patient Unique Josendan Spirin et mg daily lekoxicam o 7 3 mg daily Patient Unique Josendan	Patient (Accest(A)) Atorvisiatin Po 40 ng caty Calcium Carbonate Po 500 ng tro co Metoproiol Po 50 ng caty Metoproiol	Identical (Accelarinicophen Po 325 mg effe Calcitrol Pro 8 25 mg daily Darbepoetin so 6 mg daily Po dagened Ramippil Po 5 mg daily Po for ga daily Po for ga daily Po for ga daily	E.R. (scat.40) Alovestatin Po 60 mg day Calcium Carbonate po 1000 mg TID CC Metoproiol po 100 mg BD	Ciproflaxocin Po 560 mg dairy Ferrous Gloconate Po 200 mg 10 Omeprazole Po 40 mg dairy
Patient Unique discaldua spirin teloxicam patient 0.75 mg daily vinList Reading Patient Uscaldua spirin	Patient /Accest.do A	Identical (desst40) Acdaminophen P0 320 mg en Calcitrol P0 625 mg daly Darbepoetin sc 60 mg enday Docusate Sodium P0 100 mg 80 Ramppil P0 5 mg daly Find Identical Find Identical Identical Acetaminophen	E.R. Licost AB Alorvistatin P0 60 mg daly Calcium Carbonate P0 1000 mg TD CC Metoprotol P0 100 mg BID Fond Similar E.R. Similar Licost AB	Ciproflaxocin Po 560 mg dairy Ferrous Gloconate Po 200 mg 10 Omeprazole Po 40 mg dairy
Patient Unique discaldua spirin teloxicam patient 0.75 mg daily vinList Reading Patient Uscaldua spirin	Patient (Accest(A)) Atorvisiatin Po 40 ng caty Calcium Carbonate Po 500 ng tro co Metoproiol Po 50 ng caty Metoproiol	Identical (Accelaring of the second of the s	E.R. (scat.40) Alovestatin Po 60 mg day Calcium Carbonate po 1000 mg TID CC Metoproiol po 100 mg BD	Ciproflaxocin Po 560 mg dairy Ferrous Gloconate Po 200 mg 10 Omeprazole Po 40 mg dairy
Patient Unique decadua decadua septim feloxicam 0 75 mg daily 0 75 mg daily vinList Read Liccond.dail Patient Uscond.dail Septim	Patient (Accest.d) Atorvistatin Po 40 mg cary Calcium Carbonate Po 50 mg to cc Metoproiol Po 50 mg cary Somg cary Po 50 mg cary	Identical (Accelaringphen Po 325 mg del Calcitrol Pro 325 mg del Calcitrol Pro 625 mg daily Datospoetin SC 6 mg delay Po 100 mg BCO Identical (Accelaringphen Po 325 mg del	E.R. (Locat.40) Alovestatin Po 60 mg day Calcium Carbonate po 1000 mg Tib CC Metoproiol po 100 mg SiD	Ciproflaxocin Po 560 mg dairy Ferrous Gloconate Po 200 mg 10 Omeprazole Po 40 mg dairy E.R. Unique (Accettable
Patient Uncost di Aspirin Aspirin Po 3 fmg daily Meloxicam Po 7.5 mg daily Patient Uncost.do	Patient (AccestAD) Aloxistatin Po 40 mg carty Cacium Carbonste Po 500 mg bo CC Metoproiol Po 50 mg carty est View Patient Cacicum Carbonste Po 40 mg carty Cacicum Carbonste	Identical (Accelaring of the second of the s	E.R. (Jocati AD) Alorvisitatin Po 60 mg day Calcium Carbonate po 100 mg BD Metoprolol po 100 mg BD E.R. E.R. Similar Metogradus Calcium Carbonate	Ciproflaxocin Po 500 mg daily Ferrous Gioconate Po 300 mg TD Omeprazole Po 40 mg daily Ciproflaxocin Po 500 mg daily
Patient Unique Accention Aspirin PO 81 mg daily Meloxicam PO 75 mg daily WinList Res Patient	Patient (AccestAD) Aloxistatin Po 40 mg carty Cacium Carbonste Po 500 mg bo CC Metoproiol Po 50 mg carty est View Patient Cacicum Carbonste Po 40 mg carty Cacicum Carbonste	Identical (Acataninophen po 325 mg e8 Calcitrol pro 825 mg e8 Calcitrol pro 825 mg e8 Calcitrol po 100 mg BO Identical Acataninophen po 325 mg e8 Calcitrol po 325 mg e8 Calcitrol po 325 mg e8	E.R. (Jocati AD) Alorvisitatin Po 60 mg day Calcium Carbonate po 100 mg BD Metoprolol po 100 mg BD E.R. E.R. Similar Metogradus Calcium Carbonate	Ciproflaxocin PO 500 mg daily Ferrous: Gloconate PO 40 mg daily Ciproflaxocin Ciproflaxocin

Original layout: two separate lists

Step 1: The identical drugs move to the middle

 $\rightarrow \leftarrow$



 \rightarrow

←

Step 3: The similar drugs are aligned, with their differences highlighted (here dosage differences

Figure 4: The 4 steps of the animation sequence sorting two lists of medications. We highly recommend that you watch the video demonstration at: <u>http://www.cs.umd.edu/hcil/sharp/slides/twinlist-v2-symposium-1024by768.mp4</u>.




Figure 5. The TwinList interface: In the list viewer identical items appear in the center column, unique items in the outer columns and similar items in between. Color highlighting is used to indicate the differing attribute values. In the bottom left panel is the Accepted list; in the upper right panel, the Filter Panel; and in the lower right, the Details Panel, which displays all attributes for the selected item. In normal operation only the list viewer would be shown, until all the medications have been reconciled and the final accepted list can be approved.

Conclusions

We described a novel interface for medication reconciliation that uses animation and layout to indicate similarities and differences in pairs of medication lists and assist physicians enter their decisions regarding what to keep and what to discontinue. We are starting to gather feedback from representative users (physicians who do medication reconciliation in their daily practices). We are receiving positive feedback and continue refining our prototype. While the many issues that arise during the information gathering stages of medication reconciliation remain, we believe that Twinlist demonstrates that improved interface designs can facilitate the later stages of the reconciliation process.

Acknowledgments

This work is supported in part by Grant No. 10510592 for Patient-Centered Cognitive Support under the Strategic Health IT Advanced Research Projects Program (SHARP) from the Office of the National Coordinator for Health Information Technology. We particularly thank the physicians we interviewed for their feedback on the design, and Sumit Arora for his assistance during early parts of the project.

For more information see: http://www.cs.umd.edu/hcil/sharp

References

- 1. Joint commission on accreditation of healthcare organizations: Using medication reconciliation to prevent errors. Sentinel Event Alert, pages 1–4, January 2006
- 2. Roughead EE, Semple SJ. Medication safety in acute care in Australia: where are we now? Part 1: a review of the extend and causes of medication problems. Aust New Zealand Health Policy. 2009;6:18.
- 3. De Koning JS, Klazinga NS, Koudstaal PJ, Prins A, Dippel DW, Heerings J, et al. Quality of care in stroke prevention: results of an audit study among general practitioners. Prev Med. 2004;38:129-36.
- 4. Poon EG. Medication reconciliation: whose job is it? AORN J. 2009 Jun;89(6):1180, 1122.
- 5. Ellitt GR, Engblom E, Aslani P, Westerlund T, Chen TF. Drug related problems after discharge from an Australian teaching hospital. Pharm World Sci. 2010.
- P. Pronovost, D. B. Hobson, K. Earsing, E. S. Lins, M. L. Rinke, K. Emery, S. M. Berenholtz, P. A. Lipsett, and T. Dorman. A practical tool to reduce medication errors during patient transfer from an intensive care unit. Journal of Clinical Outcomes Management, 11(1):26, 29–33 (14 ref), 2003.
- Markowitz, E., Bernstam, E., Herskovic, J., Zhang, J., Shneiderman, B., Plaisant, C., Johnson, T. Medication Reconciliation: Work Domain Ontology, Prototype Development, and a Predictive Model, to appear in AMIA Fall conference 2011
- 8. TwinList class project: https://wiki.cs.umd.edu/cmsc734_11/index.php?title=TwinList

Proceedings of the Workshop on Interactive Systems in Healthcare (WISH 2011). Copyright retained by the authors.